Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Covington
Fish and Richardson
Dow
Mallinckrodt
McKinsey
Colorcon
Cantor Fitzgerald
US Department of Justice

Generated: July 15, 2018

DrugPatentWatch Database Preview

MEDICIS Company Profile

« Back to Dashboard

Summary for MEDICIS
International Patents:138
US Patents:24
Tradenames:19
Ingredients:17
NDAs:20
Patent Litigation for MEDICIS: See patent lawsuits for MEDICIS

Drugs and US Patents for MEDICIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-008 Aug 27, 2010 RX Yes No 7,790,705 ➤ Sign Up ➤ Sign Up
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-004 Jul 23, 2009 AB RX Yes No 5,908,838 ➤ Sign Up ➤ Sign Up
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-005 Jul 23, 2009 AB RX Yes Yes 5,908,838 ➤ Sign Up ➤ Sign Up
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-002 May 8, 2006 DISCN Yes No 5,908,838 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for MEDICIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-004 Jul 23, 2009 5,908,838 ➤ Sign Up
Medicis METROGEL-VAGINAL metronidazole GEL;VAGINAL 020208-001 Aug 17, 1992 4,837,378 ➤ Sign Up
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-005 Jul 23, 2009 5,908,838 ➤ Sign Up
Medicis MAXAIR pirbuterol acetate AEROSOL, METERED;INHALATION 020014-001 Nov 30, 1992 4,664,107 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MEDICIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 0.77% ➤ Subscribe 2006-05-10
➤ Subscribe Cream 5% ➤ Subscribe 2006-10-17
➤ Subscribe Extended-release Tablets 65 mg and 115 mg ➤ Subscribe 2009-11-19
➤ Subscribe Extended-release Tablet 105 rng ➤ Subscribe 2010-12-28
➤ Subscribe Cream 3.75% ➤ Subscribe 2012-08-08
➤ Subscribe Cream 0.10% ➤ Subscribe 2008-01-31
➤ Subscribe Vaginal Gel 0.75% ➤ Subscribe 2004-09-02
➤ Subscribe Extended-release Tablet 55 mg and 80 mg ➤ Subscribe 2010-12-02
➤ Subscribe Gel 1.2%/0.025% ➤ Subscribe 2010-12-17
➤ Subscribe Cream 2.5% ➤ Subscribe 2014-06-17

Non-Orange Book US Patents for MEDICIS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,835,394 Treatment for basal cell carcinoma ➤ Sign Up
6,517,847 Topical gel delivery system ➤ Sign Up
9,370,509 2.times.2.times.2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod ➤ Sign Up
7,771,733 Compositions and methods for enhancing corticosteroid delivery ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for MEDICIS Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00014 Denmark ➤ Sign Up PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
4 Finland ➤ Sign Up
595 Luxembourg ➤ Sign Up PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
C0021 Belgium ➤ Sign Up PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
AstraZeneca
Cipla
Queensland Health
Moodys
Deloitte
Express Scripts
McKinsey
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.